Vmn2r114 Inhibitors
Vmn2r114 inhibitors encompass a diverse array of chemical compounds that exert their inhibitory effects through various biochemical mechanisms. Quinidine, for example, through its role as a potassium channel blocker, can alter membrane potential, thus indirectly affecting Vmn2r114 activation which is dependent on specific membrane potential thresholds. Similarly, Imatinib, a tyrosine kinase inhibitor, has the potential to influence Vmn2r114 by targeting upstream tyrosine kinase receptors and disrupting the associated signaling pathways that may regulate Vmn2r114. Losartan, by antagonizing angiotensin II receptors, could disrupt signaling cascades that potentially cross-regulate Vmn2r114 activity. Rapamycin's inhibition of the mTOR pathway, Chelerythrine's antagonism of PKC, and BAPTA-AM's intracellular calcium chelation, all contribute to the modulation of downstream signaling pathways critical for Vmn2r114 functionality.
Continuing with the theme of pathway-specific inhibition, W-7 Hydrochloride and U73122 respectively target calmodulin and phospholipase C, both of which could play roles in Vmn2r114 signaling. SB203580's inhibition of p38 MAPK, Go 6983's pan-inhibition of PKC isoforms, NDGA's interference with lipoxygenase pathways, and LY294002's blockade of the PI3K/Akt pathway each represent strategic points within cellular signaling networks where Vmn2r114 function could be indirectly inhibited. These inhibitors, through their specific actions on varied signaling moleculesand pathways, can diminish Vmn2r114's activity, thus showcasing the intricate interconnectivity of cellular signaling and the potential for targeted chemical intervention.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Quinidine | 56-54-2 | sc-212614 | 10 g | $104.00 | 3 | |
Quinidine is a potassium channel blocker that could indirectly inhibit Vmn2r114 function by altering the membrane potential, which is crucial for receptor activation and signaling. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that could affect Vmn2r114 by inhibiting upstream tyrosine kinase receptors that might be involved in the regulation or modulation of Vmn2r114 signaling pathways. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan is an angiotensin II receptor antagonist that could potentially disrupt the angiotensin signaling that might influence the functional activity of Vmn2r114 through cross-regulation mechanisms. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that could potentially decrease the functional activity of Vmn2r114 by modulating the downstream signaling pathways that are regulated by mTOR, which may be necessary for Vmn2r114 activity. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is a potent inhibitor of protein kinase C (PKC) and could inhibit Vmn2r114 by altering the PKC-mediated signaling pathways that can influence the activity of various receptors and channels. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
BAPTA-AM is a calcium chelator that can indirectly inhibit Vmn2r114 by buffering intracellular calcium levels, which are often critical for the proper functioning of receptor signaling pathways. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
W-7 Hydrochloride is a calmodulin antagonist that could dampen Vmn2r114 activity by inhibiting calmodulin-dependent processes, which could be essential for the function of Vmn2r114. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that might impede Vmn2r114 function by inhibiting p38 MAPK-dependent signaling pathways that could regulate the activity of this receptor. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go 6983 is a pan-PKC inhibitor that could inhibit Vmn2r114 by reducing PKC-mediated phosphorylation events that are potentially involved in the regulation of receptor functions. | ||||||
NDGA (Nordihydroguaiaretic acid) | 500-38-9 | sc-200487 sc-200487A sc-200487B | 1 g 5 g 25 g | $109.00 $384.00 $2190.00 | 3 | |
NDGA is a lipoxygenase inhibitor that could indirectly inhibit Vmn2r114 by altering arachidonic acid metabolism, which can modulate the activity of certain receptors and channels. | ||||||